作者：
Andrés,Poveda [1]
;
Anne,Floquet [2]
;
Jonathan A,Ledermann [3]
;
Rebecca,Asher [4]
;
Richard T,Penson [5]
;
Amit M,Oza [6]
;
Jacob,Korach [7]
;
Tomasz,Huzarski [8]
;
Sandro,Pignata [9]
;
Michael,Friedlander [10]
;
Alessandra,Baldoni [11]
;
Tjoung-Won,Park-Simon [12]
;
Kenji,Tamura [13]
;
Gabe S,Sonke [14]
;
Alla,Lisyanskaya [15]
;
Jae-Hoon,Kim [16]
;
Elias Abdo,Filho [17]
;
Tsveta,Milenkova [18]
;
Elizabeth S,Lowe [19]
;
Phil,Rowe [18]
;
Ignace,Vergote [20]
;
Eric,Pujade-Lauraine [21]
;
SOLO2/ENGOT-Ov21 investigators
作者单位：
Initia Oncology, Hospital Quirónsalud, Valencia, Spain; Grupo Español de Investigación en Cáncer de Ovario, Madrid, Spain. Electronic address: apoveda@initiaoncologia.com.
[1]
Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France.
[2]
UCL Cancer Institute, University College London, London, UK; National Cancer Research Institute, London, UK.
[3]
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
[4]
Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
[5]
Princess Margaret Cancer Centre, Toronto, ON, Canada.
[6]
Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel; Israeli Society of Gynecologic Oncology, Ramat Gan, Israel.
[7]
International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland; Read-Gene SA, Grzepnica, Szczecin, Poland.
[8]
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy; Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Naples, Italy.
[9]
University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia.
[10]
Istituto Oncologico Veneto, Padova, Italy; Mario Negri Gynecologic Oncology Group, Milan, Italy.
[11]
Hannover Medical School, Hannover, Germany; German Society of Gynecological Oncology, Essen, Germany.
[12]
National Cancer Center Hospital, Tokyo, Japan.
[13]
The Netherlands Cancer Institute, Amsterdam, Netherlands; Dutch Gynecological Oncology Group, Amsterdam, Netherlands.
[14]
St Petersburg City Clinical Oncology Dispensary, St Petersburg, Russia.
[15]
Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, South Korea; Korean Gynecologic Oncology Group, Seoul, South Korea.
[16]
Instituto do Câncer do Estado São Paulo-Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
[17]
AstraZeneca, Cambridge, UK.
[18]
AstraZeneca, Gaithersburg, MD, USA.
[19]
University Hospital Leuven, Leuven Cancer Institute, Belgium; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium.
[20]
Association de Recherche Contre les Cancers dont Gynécologiques-ARCAGY, Paris, France.
[21]
DOI
10.1016/S1470-2045(21)00073-5
PMID
33743851
发布时间
2024-06-27
换一批
换一批
